跳至主要内容
临床试验/JPRN-UMIN000040511
JPRN-UMIN000040511已完成未知

Prevalence of HRR-related genes mutations and prognosis in metastatic castration resistant prostate cancer (mCRPC) patients in real world setting(ZENSHIN Study) - Prevalence of HRR-related genes mutations and prognosis in metastatic castration resistant prostate cancer (mCRPC) patients in real world setting(ZENSHIN Study)

AstraZeneca K.K.0 个研究点目标入组 155 人开始时间: 2020年5月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
155

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1. Patients who have failed HRR-related gene mutation testing with the myChoice HRD plus in screening period. 2. Patients who have an only FFPE primary tumor sample (primary or metastatic) with unbuffered formalin including acidic formalin. 3. Patients who have taken an investigational medical product for prostate cancer from Jan 1st , 2014 to Dec 31st 2020.

研究者

相似试验